High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: Implications for personalized medicine

Keyphrases

• Acute Myeloid Leukemia 100%
• Personalized Medicine 100%
• FLT3 mutation 100%
• Pediatric Leukemia 100%
• WT1 mutation 100%
• Disease Progression 100%
• Time to Relapse 100%
• All Pediatric 50%
• Therapeutic Target 50%
• Activating mutation 50%
• Initial Diagnosis 50%
• Adverse Outcomes 50%
• Risk Stratification 50%
• Individualized Treatment 50%
• Dismal Prognosis 50%
• Pediatric Patients 50%
• Complete Remission 50%
• Disease Stage 50%
• Personalized Treatment 50%
• Large Group 50%
• Induction Therapy 50%
• Disease-causing mutations 50%
• Patient's Will 50%
• Mutation Status 50%
• RAS Gene 50%
• Cell Selection 50%
• Molecular Aberrations 50%
• Cancer Cell Detection 50%

Medicine and Dentistry

• Personalized Medicine 100%
• Acute Myeloid Leukemia 100%
• Pediatric Acute Myeloid Leukemia 100%
• Disease Exacerbation 100%
• Disease 50%
• Risk Stratification 50%
• Adverse Outcome 50%
• Pediatrics Patient 50%